Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Clinical trials stories

Nov 16, 2026

FDA approves Roche's oral breast cancer pill Wilserdly

The FDA approved Roche's oral treatment for estrogen receptor-positive, HER2-negative advanced breast cancer, providing a new option for patients and a significant commercial boost for the Swiss drugmaker.

Nov 16, 2026·3 sources
00

Novo Nordisk's Wegovy shows weight-loss benefit in children as young as six

Novo Nordisk released full Phase 3 trial results showing Wegovy lowered BMI and obesity rates in children aged 6 and older, though younger children who took the drug showed reduced growth rates.

Nov 16, 2026·3 sources
00

CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3

CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.

Nov 16, 2026·3 sources
00
Nov 15, 2026

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.

Nov 15, 2026·2 sources
00
Nov 14, 2026

Eli Lilly releases new obesity drug clinical trial data at ObesityWeek

Eli Lilly released new clinical trial data for its obesity drugs at the ObesityWeek 2026 medical conference, showing weight loss benefits, though full results have not yet been published.

Nov 14, 2026·2 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00

Novo submits sickle cell drug for regulatory approval

Novo Nordisk has submitted a sickle cell disease drug for regulatory approval, a medicine acquired in a billion-dollar deal that the company views as a future blockbuster.

Nov 13, 2026·2 sources
00

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources
00
Nov 11, 2026

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Pfizer has struck a deal with Blackstone to receive up to $1.5 billion through 2028 to fund development of an experimental monthly obesity treatment, as the company races to compete in the GLP-1 market without a currently approved weight-loss drug.

Nov 11, 2026·3 sources
00

Amgen's Sjögren's drug cuts disease activity in trial

Amgen reported positive trial results showing its experimental drug reduced disease activity in patients with Sjögren's syndrome, a chronic autoimmune condition with limited treatment options.

Nov 11, 2026·2 sources
00
Nov 10, 2026

FDA approves Merck KGaA's pimicotinib for tenosynovial giant cell tumor

The FDA has approved pimicotinib (Pimjetmi, EMD Serono) for treating symptomatic tenosynovial giant cell tumors where surgery would worsen functional limitations, marking another win for Merck KGaA's rare tumor strategy.

Nov 10, 2026·3 sources
00

Beam Therapeutics base-editing sickle cell therapy succeeds in pivotal trial

Beam Therapeutics announced its base-edited sickle cell therapy met its primary endpoint in a Phase 1/2 clinical trial, potentially positioning it as a third one-time curative therapy for the disease.

Nov 10, 2026·2 sources
00
Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00
Nov 8, 2026

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 2026·2 sources
00
Nov 6, 2026

Sarepta halts enrollment in confirmatory Phase 3 trial of Elevidys

Sarepta Therapeutics announced it will not enroll additional patients in the confirmatory Phase 3 trial of Elevidys, its Duchenne muscular dystrophy gene therapy, a study required to maintain the drug's accelerated approval.

Nov 6, 2026·2 sources
00

Moderna posts first quarterly profit in two years, raises revenue forecast

Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.

Nov 6, 2026·5 sources
00
Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 2026·2 sources
00

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

New data from Amgen showed its PCSK9 inhibitor Repatha reduced heart attack risk by approximately 20% more than Zetia (ezetimibe) in patients where statins are insufficient.

Nov 5, 2026·2 sources
00
Nov 4, 2026

NHS England to roll out multi-cancer blood tests to 200 GP surgeries

New blood tests designed to detect multiple cancers simultaneously will be offered to NHS patients in approximately 200 GP surgeries in England as part of an expanded pilot program.

Nov 4, 2026·2 sources
00
Nov 3, 2026

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 2026·2 sources
00
Nov 2, 2026

Cerus blood-safety system meets primary endpoint in late-stage trial

Cerus Corp announced that red blood cells treated with its blood-safety technology performed as well as conventional red blood cells in patients requiring transfusions in a late-stage study.

Nov 2, 2026·2 sources
00

FDA sets May 2027 review date for uniQure's Huntington's gene therapy

The FDA will review uniQure's gene therapy for Huntington's disease, with a decision expected in May 2027. The agency has also scheduled an advisory committee meeting.

Nov 2, 2026·2 sources
00

Novartis heart drug failure raises questions about genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.

Nov 2, 2026·2 sources
00
Nov 1, 2026

Setara Biosciences launches with $90M for rare disease drug development

Setara Biosciences has started operations with $90 million in funding and a lead drug candidate already in clinical trials for Charcot-Marie-Tooth disease type 2C and overactive bladder.

Nov 1, 2026·4 sources
00
Oct 30, 2026

First patient receives Sumitomo Pharma stem cell transplant for Parkinson's disease

A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.

Oct 30, 2026·3 sources
00

FDA approves tildrakizumab for psoriatic arthritis

The FDA cleared Sun Pharma's interleukin-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis in adults, expanding the drug's approved indications.

Oct 30, 2026·3 sources
00

PinkDx vaginal swab test could detect endometrial cancer without painful biopsy

A new vaginal swab test developed by molecular diagnostics company PinkDx may help women with abnormal bleeding detect endometrial cancer without undergoing a painful biopsy. The development comes as death rates from endometrial cancer, one of the most common cancers in women, are increasing.

Oct 30, 2026·5 sources
00

Norrin treatment prevents vision loss in diabetic rats, study finds

Research shows that treatment with norrin helps maintain healthy blood vessels in the retina and preserves vision in diabetic rats, offering potential hope for treating diabetic retinopathy, a complication affecting over 100 million people in the U.S.

Oct 30, 2026·2 sources
00

UCSF launches trial of wearable ultrasound device to treat schizophrenia hallucinations

The University of California, San Francisco opened the MESSI-LEO Phase 1 trial on October 30, testing a wearable 128-element ultrasound headband that targets the caudate region of the brain to reduce auditory hallucinations in schizophrenia patients. The noninvasive treatment addresses persistent hallucinations that affect approximately 40% of patients despite antipsychotic medications.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Stem cell transplants show 60% progression-free survival at 10 years for severe systemic sclerosis

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.

Oct 29, 2026·3 sources
00

Twice-during-pregnancy STI screening reduces preterm birth risk by 23%, study finds

A randomized clinical trial published in Clinical Infectious Diseases found that screening and treating pregnant patients for three common sexually transmitted infections twice during pregnancy was associated with a 23% lower risk of preterm birth compared with standard care.

Oct 29, 2026·3 sources
00

Dren Bio raises $350 million for blood cancer drug ahead of potential 2027 launch

California biotech Dren Bio secured $350 million in funding to advance its lead blood cancer therapy toward a potential market launch by the end of 2027.

Oct 29, 2026·3 sources
00

Study finds one in four users discontinue insomnia drug lemborexant due to side effects

Researchers from Rutgers and other universities analyzed hundreds of online reviews of lemborexant, a prescription insomnia medication, and found that approximately 25% of reviewers stopped or planned to stop taking the drug due to troubling side effects.

Oct 29, 2026·2 sources
00

iDIET shows improved outcomes for eosinophilic esophagitis in randomized trial

A novel allergen-specific, immune signature-directed diet (iDIET) led to significant improvements in histologic and endoscopic responses in patients with eosinophilic esophagitis compared with a sham elimination diet, according to results from a small randomized study presented in Nashville, Tennessee.

Oct 29, 2026·1 source
00

MIT researchers develop magnetic bead implants for prosthetic limb control

MIT researchers have demonstrated that tiny magnetic beads implanted in muscle tissue can accurately track muscle movement, offering a new method for controlling prosthetic limbs. The wireless system uses skin-mounted magnetometers to track the implanted beads, achieving precision that matches or exceeds traditional electromyography methods.

Oct 29, 2026·4 sources
00
Oct 28, 2026

Genmab's petosemtamab cuts death risk by half in head and neck cancer trial

Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.

Oct 28, 2026·3 sources
00

SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial

A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.

Oct 28, 2026·2 sources
00

Formation raises $600 million to accelerate AI drug development

AI biotech startup Formation Bio raised $600 million to acquire or license stalled drug candidates and use AI to accelerate clinical trials, addressing what it sees as the real bottleneck in drug development.

Oct 28, 2026·2 sources
00

Eli Lilly's retatrutide outperforms Ozempic in head-to-head diabetes trial

Eli Lilly announced its experimental obesity drug retatrutide delivered more than double the weight loss and superior blood sugar control compared to Novo Nordisk's Ozempic in a head-to-head clinical trial for type 2 diabetes.

Oct 28, 2026·3 sources
00

High-volume injections for Achilles tendinopathy show no benefit over placebo in clinical trial

A clinical trial published in The BMJ found that commonly used injections for Achilles tendinopathy—including high-volume saline, local anesthetic, and low-dose corticosteroid—offer no meaningful clinical advantage over sham treatment. The findings add to ongoing controversy about corticosteroid injections for tendon conditions.

Oct 28, 2026·3 sources
00
Oct 27, 2026

Ferring to acquire fertility startup Gameto for up to $1.38B

Ferring Pharmaceuticals has signed an agreement to acquire fertility startup Gameto in a deal worth up to $1.3825 billion, expanding its reproductive health portfolio.

Oct 27, 2026·2 sources
00

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Artiva Biotherapeutics halted development of its experimental cell therapy for autoimmune conditions following two patient deaths in clinical trials and announced massive workforce reductions.

Oct 27, 2026·4 sources
00

Bevacizumab and pazopanib combination extends survival in kidney cancer trial

A phase 1/2 trial led by Roswell Park Comprehensive Cancer Center found that combining bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with metastatic clear-cell renal cell carcinoma, the most common type of kidney cancer. The study established a safe dosing regimen and demonstrated promising antitumor activity in treatment-naive patients.

Oct 27, 2026·2 sources
00

Novartis raises profit guidance despite $1.9 billion drug trial setback

Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.

Oct 27, 2026·2 sources
00
Oct 26, 2026

Congo Ebola cases surpass 10,000 as health worker killed in attack

Democratic Republic of Congo's Ebola outbreak has exceeded 10,000 confirmed cases, with violence against health workers intensifying after a nurse was killed responding to the epidemic.

Oct 26, 2026·2 sources
00

Merck drug extends survival in endometrial cancer, wins FDA priority review

Merck's experimental antibody-drug conjugate reduced death risk by one-third in advanced endometrial cancer patients and received FDA priority review based on late-stage trial data.

Oct 26, 2026·3 sources
00

Heart drug combination reduces kidney damage in septic shock surgery, major trial finds

A major trial published in JAMA shows that a simple adjustment to drugs given during operations for septic shock could prevent thousands of patients from suffering kidney damage. Scientists from the University of Southampton and Zhejiang University School of Medicine conducted the research.

Oct 26, 2026·2 sources
00

GSK to nearly double cancer drugs in clinical trials by 2027

GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.

Oct 26, 2026·5 sources
00

FDA expands talazoparib approval for metastatic prostate cancer

The FDA approved the PARP inhibitor talazoparib in combination with enzalutamide for treatment of patients with metastatic androgen pathway modulation-naive or -sensitive prostate cancer.

Oct 26, 2026·2 sources
00

Genmab's ovarian cancer drug cuts death risk 57% in late-stage trial

Genmab's experimental antibody-drug conjugate Rina-S reduced the risk of death by 57% compared to chemotherapy in patients with advanced ovarian cancer, according to phase 3 trial results presented at ESMO. The Danish drugmaker's shares surged over 12% on the news.

Oct 26, 2026·2 sources
00

Bayer wins China approval for stroke prevention drug asundexian

China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.

Oct 26, 2026·3 sources
00
Oct 25, 2026

Roche's divarasib cuts death risk 44% in lung cancer trial vs Amgen, Bristol Myers drugs

Roche's next-generation KRAS G12C inhibitor divarasib reduced the risk of death by 44% compared to current treatments in previously treated mutant non-small cell lung cancer patients, with median overall survival reaching nearly 6 months longer than competitors.

Oct 25, 2026·4 sources
00

AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial

AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.

Oct 25, 2026·2 sources
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00

Nearly 30% of advanced melanoma patients achieve complete tumor disappearance with lifileucel TIL therapy plus pembrolizumab

Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.

Oct 24, 2026·1 source
00
Oct 23, 2026

Tegoprubart outperforms tacrolimus in preserving kidney function after transplant, BESTOW trial finds

The Phase 2 BESTOW clinical trial demonstrated that tegoprubart, a novel anti-CD40L antibody therapy, was superior to tacrolimus, the current standard of care, at preserving kidney function in adults receiving their first kidney transplant. The trial results suggest a potential advancement in immunosuppressive treatment regimens for transplant patients.

Oct 23, 2026·3 sources
00

Online resources and coaching increased cancer genetic testing uptake in University of Michigan study

A University of Michigan Rogel Cancer Center study found that online resources combined with phone-based coaching helped more eligible cancer patients complete genetic testing. About 10% of cancers are linked to inherited genetic variants, but as few as 1 in 15 eligible patients currently complete testing, with lack of knowledge being a key barrier.

Oct 23, 2026·3 sources
00

Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years

Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.

Oct 23, 2026·2 sources
00

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

Bristol Myers patient died after CAR-T treatment, company explains June trial pause

Bristol Myers Squibb disclosed that a multiple sclerosis patient died from septic pneumonia following zola-cel CAR-T treatment, linking prior adverse events to manufacturing reagent changes. The company plans to restart trials in early 2025.

Oct 23, 2026·5 sources
00

Bristol Myers Squibb and SystImmune breast cancer drug reduces disease progression risk by 59% in phase 3 trial

Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.

Oct 23, 2026·4 sources
00

Novartis breast cancer drug Kisqali cuts death risk by 19% after six years in early-stage trial

Novartis reported that its drug Kisqali helped extend survival for women with high-risk, early-stage breast cancer, cutting their risk of death by 19% after six years in trial data.

Oct 23, 2026·2 sources
00

Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics reported an 82% tumor response rate in a clinical trial combining targeted drugs for advanced pancreatic cancer, presented at ESMO congress.

Oct 23, 2026·2 sources
00

Johnson & Johnson prostate cancer drug JNJ-6143 shows tumor shrinkage in early-stage trial

Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.

Oct 23, 2026·4 sources
00

Star Therapeutics raises $200 million to advance pipeline after spinout successes

Star Therapeutics has secured $200 million in private financing to advance its preclinical programs into clinical trials and expand its pipeline. The funding follows the company's successful track record of spinning out companies including Vega and Electra, with Incyte acquiring one of its spinouts in July 2026.

Oct 23, 2026·5 sources
00

New analysis shows daraxonrasib survival benefits across patient groups in advanced pancreatic cancer

A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.

Oct 23, 2026·4 sources
00
Oct 22, 2026

Fruits and vegetables outperform sodium bicarbonate for treating metabolic acidosis in chronic kidney disease

A recent clinical trial found that dietary acid reduction using base-producing fruits and vegetables is more effective than the standard oral sodium bicarbonate treatment for metabolic acidosis in people with chronic kidney disease. The findings will be presented at ASN Kidney Week.

Oct 22, 2026·3 sources
00

Trump administration proposes restrictions on US investment in Chinese biotech sector

The Treasury Department issued proposed rules that would severely restrict future US investment in Chinese biotechnology companies, potentially complicating financial ties as American drugmakers increasingly turn to China for clinical trials and manufacturing.

Oct 22, 2026·5 sources
00

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00

FDA approves dolutegravir HIV drug for newborns based on international clinical trial

The U.S. Food and Drug Administration has approved dolutegravir, a second-generation antiretroviral drug, for use in newborns exposed to HIV-1. The approval was informed by an international phase 1 study conducted through the IMPAACT Network that established safe and effective dosing regimens for full-term neonates.

Oct 22, 2026·3 sources
00
Oct 21, 2026

Roivant's brepocitinib succeeds in phase 3 trials for non-infectious uveitis

Roivant Sciences and subsidiary Priovant Therapeutics announced that brepocitinib met all primary and secondary endpoints in two phase 3 trials (CLARITY-1 and CLARITY-2) for non-infectious uveitis, an inflammatory eye condition. The results come shortly after the drug won approval for dermatomyositis, with analysts calling it potentially "best-in-disease" and superior to Humira.

Oct 21, 2026·7 sources
00
Oct 20, 2026

Novo Nordisk's CagriSema shows 25% weight loss in women in late-stage analysis

Novo Nordisk reported that its next-generation obesity drug CagriSema achieved 25% average weight loss in women with obesity or overweight in a post-completion analysis of late-stage trial data.

Oct 20, 2026·2 sources
00

Rapport Therapeutics' RAP-219 meets primary endpoint in phase 2 bipolar mania trial

Rapport Therapeutics announced positive phase 2 results for RAP-219, an oral AMPA receptor modulator licensed from Johnson & Johnson, showing improvement in bipolar mania symptoms. This marks the company's second phase 2 success for the asset in 14 months.

Oct 20, 2026·3 sources
00

ARCTIC trial shows excellent 10-year outcomes with treat-to-target strategy in early rheumatoid arthritis

A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.

Oct 20, 2026·2 sources
00
Oct 19, 2026

Carotid artery stenting fails to improve cognition in CREST-H clinical trial

A Columbia-led clinical trial published in JAMA found that opening blockages in the brain's main blood vessels through stenting or surgery does not improve cognitive function, despite hopes that improved blood flow would enhance cognition in patients with clogged carotid arteries.

Oct 19, 2026·1 source
00

FDA grants accelerated approval to dostarlimab for dMMR rectal cancer

The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.

Oct 19, 2026·4 sources
00

Gilead's emvistegrast eliminates symptoms in ulcerative colitis Phase 2 trial

Gilead Sciences reported mid-stage study results showing its oral α4β7 inhibitor emvistegrast eliminated symptoms in patients with ulcerative colitis, with remission rates exceeding those of Entyvio. The company plans to begin late-stage trials in 2027.

Oct 19, 2026·2 sources
00

Mirikizumab achieves clinical remission in pediatric ulcerative colitis phase 3 trial

Eli Lilly's mirikizumab (Omvoh) achieved clinical and endoscopic remission rates in children with ulcerative colitis that exceeded historical adult placebo outcomes at week 12 in the SHINE-2 phase 3 study. The positive pediatric data could provide a competitive advantage for the IL-23p19 inhibitor in the inflammatory bowel disease market.

Oct 19, 2026·3 sources
00

Disc Medicine's erythropoietic protoporphyria drug succeeds in late-stage trial

Disc Medicine's experimental pill for erythropoietic protoporphyria, a rare disease causing extreme pain from sunlight, met all primary and secondary goals in a late-stage trial, sending shares surging.

Oct 19, 2026·2 sources
00

Gilead's oral drug succeeds in mid-stage inflammatory bowel disease trial

Gilead Sciences reported that its oral treatment eliminated symptoms in patients with inflammatory bowel disease in a mid-stage clinical trial.

Oct 19, 2026·2 sources
00
Oct 16, 2026

Novartis terminates Fabhalta mid-stage trial in lupus nephritis

Novartis has ended a mid-stage clinical trial testing Fabhalta in patients with lupus nephritis, citing 'strategic considerations' according to federal clinical trial records.

Oct 16, 2026·2 sources
00
Oct 15, 2026

Osivax's flu vaccine OVX836 fails Phase 2b trial, company pivots to combination approach

French biotech Osivax announced that its lead influenza vaccine OVX836 did not meet its pre-specified primary endpoint in a Phase 2b trial, though the company reported a first consistent efficacy signal for a monovalent nucleoprotein-based influenza vaccine across both major influenza A subtypes. Osivax plans to advance a combination strategy for next-generation seasonal influenza vaccines.

Oct 15, 2026·2 sources
00

Dexcom G7 study shows continuous glucose monitoring benefits type 2 diabetes patients not on insulin

A landmark study published in The New England Journal of Medicine found that continuous glucose monitoring devices benefit all type 2 diabetes patients, including those not taking insulin, with users achieving lower HbA1c levels and spending approximately 5 more hours per day in target glucose range. The Dexcom CONNECT study marks the first standalone real-time CGM clinical data published in NEJM in nearly two decades.

Oct 15, 2026·4 sources
00
Oct 14, 2026

Vanda Pharmaceuticals halts social anxiety drug program after Phase 3 failure

Vanda Pharmaceuticals' experimental drug VQW-765 for social anxiety disorder failed the main goal of a late-stage study in female patients, prompting the company to put the program on hold pending further analysis.

Oct 14, 2026·2 sources
00

Verastem raises $250M as KRAS inhibitor shows promise in pancreatic cancer

Verastem Oncology announced encouraging early results for its KRAS G12D inhibitor in pancreatic cancer patients alongside a $250 million fundraise and CEO departure, positioning itself as a competitor to Revolution Medicines in next-generation KRAS treatments.

Oct 14, 2026·3 sources
00

FDA launches comprehensive review of rare disease drug approval process

The U.S. Food and Drug Administration is initiating a top-to-bottom review of its rare disease drug development and approval framework, aiming to standardize its approach to scientific evidence and prioritize consistency over flexibility. The new framework seeks to reduce uncertainty for investors and bring rare disease therapies to patients faster.

Oct 14, 2026·5 sources
00

Merck CEO says cancer vaccine with Moderna will become faster to manufacture

Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.

Oct 14, 2026·4 sources
00
Oct 13, 2026

New trial to examine GLP-1 drugs' impact on criminal justice interactions, employment and housing

A newly announced clinical trial will test whether GLP-1 weight loss drugs can improve outcomes related to criminal justice system interactions, employment, and housing stability, expanding beyond existing trials examining the medications' effects on substance use disorders and other health conditions.

Oct 13, 2026·4 sources
00
Oct 12, 2026

Iodine-124 evuzamitide PET/CT test shows promise for early cardiac amyloidosis detection

An investigational radiotracer test, iodine-124 evuzamitide PET/CT, demonstrated accurate diagnosis and quantification of cardiac amyloidosis in a single noninvasive scan, detecting early disease missed by other diagnostic methods. Results from the REVEAL study were presented at the Heart Failure Society of America Annual Scientific Meeting, with the test now headed for FDA review.

Oct 12, 2026·3 sources
00
Oct 9, 2026

Prediction markets enter pharmaceutical drug trials, raising integrity concerns

Prediction marketplaces are expanding into the pharmaceutical field, allowing users to buy and sell shares on clinical trial outcomes. Experts warn this development may threaten the integrity of drug trials as the platforms take their first steps into this new territory.

Oct 9, 2026·4 sources
00

Semaglutide shows strong weight loss in adolescents but lacks long-term safety data on bone and growth

A study presented at a medical conference found that the GLP-1 medication semaglutide produces substantial weight loss in adolescents with obesity, with similar gastrointestinal side effects as seen in adults. However, researchers noted that trials in teens rarely assess critical developmental factors including bone density, lean mass, or neurodevelopment.

Oct 9, 2026·4 sources
00
Oct 8, 2026

NRG-BR002 trial finds ablation does not improve survival in oligometastatic breast cancer

A randomized clinical trial found that adding metastasis-directed ablation (focused radiation or surgery) to first-line systemic therapy did not improve progression-free or overall survival in patients with oligometastatic breast cancer. Two-year overall survival was 88.4% with systemic therapy alone versus 78% with ablation added.

Oct 8, 2026·2 sources
00
Oct 7, 2026

Zealand Pharma's petrelintide shows 9.2% weight loss in Phase 2 obesity trial

Zealand Pharma announced positive Phase 2 ZUPREME-2 trial results for its amylin analog petrelintide, which achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo in people with overweight or obesity and type 2 diabetes. The drug also demonstrated HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo.

Oct 7, 2026·3 sources
00

Cerevance's Parkinson's drug solengepras reduces off-time in late-stage trial

Cerevance's experimental pill solengepras helped Parkinson's disease patients control symptoms for longer periods each day in a successful late-stage clinical trial, potentially offering a new treatment option.

Oct 7, 2026·2 sources
00
Oct 6, 2026

Bangladesh considers dengue vaccine trials as outbreak kills hundreds

Bangladesh is considering clinical trials for a dengue vaccine after hundreds of deaths and thousands of hospitalizations from the mosquito-borne disease. The outbreak has worsened through September, with at least 233 deaths reported and experts warning that weather conditions could fuel further spread.

Oct 6, 2026·3 sources
00
Oct 5, 2026

Vaxcyte pneumococcal vaccine succeeds in Phase 3 trial

Vaxcyte's experimental pneumococcal vaccine generated immune responses comparable to Pfizer and Merck vaccines in a Phase 3 trial, positioning it to compete in the lucrative vaccine market.

Oct 5, 2026·3 sources
00

Optogenetic therapy shows promise in restoring vision for retinitis pigmentosa patients

A clinical trial of optogenetic therapy, based on Nobel Prize-winning research, demonstrated safety and partial vision restoration in patients with advanced retinitis pigmentosa, with 7 of 10 patients showing improved light sensitivity. The treatment uses gene therapy to engineer retinal cells to respond to light.

Oct 5, 2026·8 sources
00

Epicrispr reports updated trial data for epigenetic editing treatment in FSHD muscular dystrophy

Epicrispr Biotechnologies presented encouraging updated findings from testing of its epigenetic editing treatment for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disease. The data builds the case for the company's therapeutic approach to treating the condition.

Oct 5, 2026·2 sources
00
Oct 3, 2026

Z-basivarsen shows sustained benefits in myotonic dystrophy type 1 trial

An investigational drug, z-basivarsen, demonstrated sustained improvements in myotonia, motor function, and strength in patients with myotonic dystrophy type 1, according to analysis from the ACHIEVE trial. The findings suggest potential therapeutic benefits for this genetic neuromuscular disorder.

Oct 3, 2026·2 sources
00
Oct 2, 2026

Retatrutide shows substantial weight loss in type 2 diabetes patients in phase III trial

The investigational triple agonist retatrutide demonstrated significant weight loss and improved glycemic control in adults with obesity and type 2 diabetes in the TRIUMPH-2 phase III trial, with some participants losing up to a quarter of their body weight. Results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.

Oct 2, 2026·5 sources
00
Oct 1, 2026

Survodutide shows modest weight loss in phase 3 diabetes trial, trailing competitors

Boehringer Ingelheim's investigational dual GIP/GLP-1 agonist survodutide achieved up to 9.8% weight loss in the phase 3 SYNCHRONIZE-2 trial for adults with type 2 diabetes and obesity, meeting primary endpoints but falling short of competing drugs. The results raised tolerability concerns and led to a drop in partner Zealand Pharma's stock.

Oct 1, 2026·6 sources
00

FDA approves Camzyos for pediatric hypertrophic cardiomyopathy, first cardiac myosin inhibitor for children

The FDA has approved Bristol Myers Squibb's Camzyos (mavacamten) for treating symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients, making it the first cardiac myosin inhibitor approved for children with this painful heart condition. The approval is based on positive results from the Phase 3 SCOUT-HCM trial.

Oct 1, 2026·5 sources
00

Pfizer's tilrekimig meets primary goal in phase 2 eczema trial

Pfizer's experimental eczema drug tilrekimig achieved significantly stronger skin clearance compared to placebo at multiple doses in a mid-stage clinical trial after 16 weeks. The company presented detailed Phase 2 results for the atopic dermatitis treatment.

Oct 1, 2026·1 source
00
Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 2026·6 sources
00
Sep 29, 2026

UniQure's Huntington's gene therapy shows weaker benefit after four years

UniQure reported its gene therapy for Huntington's disease showed diminished benefits at four years compared to three years in a small trial, with shares plunging 48% as the results cast doubt on the treatment's long-term efficacy.

Sep 29, 2026·3 sources
00

Eli Lilly's retatrutide helps diabetes patients lose up to 21% body weight in late-stage trial

Eli Lilly reported that its experimental triple-agonist drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, with more than half of patients dropping below the obesity threshold.

Sep 29, 2026·3 sources
00
Sep 28, 2026

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 2026·5 sources
00

Adicet Bio's off-the-shelf CAR-T therapy shows promise in lupus trial

Adicet Bio reported positive early trial results for prula-cel, an off-the-shelf gamma delta CAR-T therapy for systemic lupus erythematosus. At 12 months, 54% of evaluable patients achieved DORIS remission with no severe side effects, surpassing benchmarks set by personalized CAR-T treatments.

Sep 28, 2026·4 sources
00

Three deaths in Novartis CAR T-cell therapy trials for autoimmune disease prompt caution

Three participants have died in clinical trials of Novartis' chimeric antigen receptor T-cell therapy for autoimmune disease, prompting physicians to approach patient discussions with greater caution as the field remains in early stages of development.

Sep 28, 2026·3 sources
00

Noninvasive ear nerve stimulation shows promise for uncontrolled high blood pressure in SCRATCH-HTN trial

A clinical trial led by Queen Mary University of London has found that transcutaneous autonomic neuromodulation through the ear is safe, well-tolerated, and easy for patients with uncontrolled hypertension to use at home. The SCRATCH-HTN trial demonstrates the potential of this noninvasive technique as a treatment option for high blood pressure.

Sep 28, 2026·3 sources
00
Sep 24, 2026

Acadia's Alzheimer's psychosis drug fails mid-stage trial

Acadia Pharmaceuticals reported its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study testing whether it could reduce hallucinations and delusions. The company said it saw enough signal to continue with a modified Phase 3 trial.

Sep 24, 2026·3 sources
00

Merck's remigromig meets primary endpoint in diabetic macular edema trial amid safety concerns

Merck announced that remigromig, a tri-specific antibody acquired in a $1.3 billion buyout, achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for diabetic macular edema. However, language regarding the drug's safety profile has raised concerns among analysts.

Sep 24, 2026·4 sources
00
Sep 22, 2026

Otsuka and Ionis' ulefnersen meets primary endpoint in phase 3 ALS trial

Otsuka Pharmaceutical and Ionis Pharmaceuticals announced their experimental drug ulefnersen met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosis (ALS), showing improvements in functional impairment and survival. The partners plan to approach the FDA to determine potential regulatory pathways.

Sep 22, 2026·6 sources
00

Celldex barzolvolimab Phase 3 trials meet endpoints but report two anaphylaxis cases

Celldex Therapeutics' barzolvolimab achieved what analysts called best-in-class efficacy results in two Phase 3 trials for chronic spontaneous urticaria, meeting all primary and key secondary endpoints. However, the trials also reported two life-threatening anaphylaxis cases, causing shares to drop 13-15% despite the positive efficacy data.

Sep 22, 2026·6 sources
00

Roche's obesity drug enicepatide cuts body weight 15.5% in mid-stage trial

Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.

Sep 22, 2026·2 sources
00
Sep 21, 2026

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00

Beacon Therapeutics' gene therapy succeeds in phase 2 trial for rare inherited eye disease

Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.

Sep 21, 2026·2 sources
00

Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in weight loss trials

Novo Nordisk announced topline results showing CagriSema achieved 12.4% weight loss versus 9.1% for tirzepatide at 60 weeks in adults with type 2 diabetes in the REIMAGINE 5 trial, and induced 21% weight loss at 68 weeks in people with overweight or obesity without diabetes in the REDEFINE trial.

Sep 21, 2026·2 sources
00

FDA grants breakthrough therapy designation for DT120 ODT in depression treatment

The FDA has granted breakthrough therapy designation to Definium Therapeutics' DT120 Orally Disintegrating Tablet after preliminary clinical evidence showed significant improvements in treating major depressive disorder.

Sep 21, 2026·1 source
00
Sep 19, 2026

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Sep 17, 2026

Roche's Lunsumio meets primary endpoint in phase 3 follicular lymphoma trial

Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.

Sep 17, 2026·2 sources
00

Clinical trial finds intrauterine mepivacaine reduces pain during IUD insertion

A placebo-controlled trial demonstrated that intrauterine instillation of the anesthetic mepivacaine effectively reduces pain during intrauterine device (IUD) placement, particularly in nulliparous patients. The findings address growing patient reports of pain during IUD insertion procedures.

Sep 17, 2026·3 sources
00
Sep 15, 2026

Atezolizumab fails primary endpoint in IMpower030 trial for resectable lung cancer

The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.

Sep 15, 2026·1 source
00
Sep 14, 2026

US, India launch initiatives to accelerate drug approval processes

The FDA is accepting applications for a pilot program to expedite drug testing in humans, while at least 19 US states have applied for a Medicaid drug-pricing experiment with international benchmarking. Separately, India's government is streamlining its drug approval process by allowing studies to begin after notifying regulators and cutting import license processing times in half.

Sep 14, 2026·3 sources
00

Scholar Rock's spinal muscular atrophy drug Isembyld approved by FDA

The FDA approved Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug will cost approximately $310,000 annually and showed improvements in motor function in clinical trials.

Sep 14, 2026·3 sources
00
Sep 11, 2026

AstraZeneca's breast cancer pill fails late-stage trial after receiving FDA approval

AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.

Sep 11, 2026·4 sources
00
Sep 10, 2026

FDA places partial clinical hold on Biohaven's epilepsy drug after rodent findings

The FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000 (opakalim), pausing new patient enrollment in trials following concerning findings in rodent studies. The hold was announced weeks after Biohaven sold rights to the therapy.

Sep 10, 2026·3 sources
00
Sep 8, 2026

AstraZeneca lung disease drug shows 30% reduction in COPD exacerbations

AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.

Sep 8, 2026·3 sources
00

AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.

Sep 8, 2026·3 sources
00

Bristol Myers CAR-T therapy shows high response rate in treatment-resistant blood cancer

Bristol Myers Squibb reported its experimental GPRC5D-directed CAR-T cell therapy achieved a high overall response rate in a mid-stage trial for patients with hard-to-treat multiple myeloma who had progressed after prior CAR-T treatment.

Sep 8, 2026·3 sources
00

BrainChild Bio raises $116M series A for pediatric brain cancer CAR-T therapy

BrainChild Bio, spun out of Seattle Children's Hospital, secured $116 million in series A funding to advance its lead CAR-T therapy BCB-276 into pivotal trials for diffuse intrinsic pontine glioma, a rare and fatal brain tumor affecting approximately 300 U.S. children annually.

Sep 8, 2026·3 sources
00
Sep 7, 2026

Novo Nordisk halts two cardiovascular trials of ziltivekimab

Novo Nordisk discontinued two additional clinical trials of its experimental cardiovascular drug ziltivekimab, further limiting the company's efforts to diversify beyond its obesity drug portfolio.

Sep 7, 2026·2 sources
00

Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial

In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.

Sep 7, 2026·2 sources
00
Sep 5, 2026

Immediate coronary angiography shows no survival benefit after cardiac arrest, trial finds

A clinical trial found that immediate coronary angiography did not improve 30-day survival rates compared to a deferred strategy in patients without ST-segment elevation on ECG following out-of-hospital cardiac arrest.

Sep 5, 2026·1 source
00

Novartis cholesterol drug pelacarsen fails in major clinical trial

Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.

Sep 5, 2026·2 sources
00
Sep 3, 2026

Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx Pharmaceuticals' apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The failure of what was once considered a potential blockbuster therapy is forcing Ultragenyx to examine significant cost cuts.

Sep 3, 2026·2 sources
00

AbbVie's etentamig succeeds in Phase 3 trial for multiple myeloma

AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.

Sep 3, 2026·3 sources
00
Sep 2, 2026

Teva's celiac disease drug prevents intestinal damage in gluten challenge trial

Teva's experimental drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge in a mid-stage study, representing potential progress for a condition with no current drug treatments.

Sep 2, 2026·2 sources
00

At-home urine test detects over 90% of bladder cancers in NHS trial

A non-invasive urine test being trialled by the NHS has been found to detect more than nine in ten bladder cancer cases in a study of 964 patients across seven NHS urology centers. The test, led by the University of Birmingham and Nonacus, could help reduce reliance on cystoscopies and waiting lists.

Sep 2, 2026·4 sources
00
Sep 1, 2026

Alumis experimental lupus drug fails primary endpoint in phase 3 trial

Alumis reported its experimental TYK2 inhibitor failed to meet the main goal of a late-stage lupus trial, though the company plans to advance the drug in a smaller subset of patients.

Sep 1, 2026·2 sources
00

GSK advances mRNA flu vaccine to late-stage trial after strong mid-stage results

GSK will advance its mRNA-based seasonal influenza vaccine to late-stage trials after mid-stage data showed it generated stronger immune responses than currently approved flu vaccines.

Sep 1, 2026·2 sources
00
Aug 31, 2026

Extended Paxlovid treatment fails to ease long COVID symptoms in 959-person trial

A clinical trial published in Lancet Infectious Diseases found that Paxlovid, an antiviral drug commonly used to treat acute COVID-19, does not alleviate long COVID symptoms when treatment is extended. The study involved 959 participants.

Aug 31, 2026·1 source
00

Sleep apnea pill reduces breathing events by 44% in phase 3 trial

A once-nightly pill cut breathing interruptions by approximately 44% in a major phase 3 sleep apnea trial, while improving oxygen levels and disease severity by strengthening airway muscles.

Aug 31, 2026·2 sources
00
Aug 28, 2026

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00
Aug 24, 2026

FDA places clinical hold on Regenxbio gene therapy after MRI abnormalities

The FDA halted testing of Regenxbio's gene therapy for Hunter Syndrome after spinal MRI scans detected abnormalities in five trial participants. This is the second clinical hold placed on a Regenxbio gene therapy program.

Aug 24, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 18, 2026

SINGLE-AF trial finds blood thinners cut stroke risk 69% in atrial fibrillation patients

The randomized SINGLE-AF trial, presented at ESC Congress 2026 and published in the New England Journal of Medicine, found that direct oral anticoagulants reduced serious clinical events by 69% in atrial fibrillation patients with intermediate stroke risk. The benefit was primarily driven by fewer ischemic strokes, with no increase in major bleeding.

Aug 18, 2026·3 sources
00
Aug 17, 2026

AstraZeneca halts late-stage lung cancer trial of volrustomig after interim analysis shows unlikely success

AstraZeneca discontinued a Phase 3 trial combining its experimental bispecific antibody volrustomig with chemotherapy for lung cancer after an interim data review indicated survival goals would likely not be met. This marks another setback for the company's pipeline as it pursues an $80 billion sales target.

Aug 17, 2026·3 sources
00
Aug 15, 2026

Innovent Biologics doses first patient in phase 3 trial of IBI363 for advanced colorectal cancer

Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.

Aug 15, 2026·1 source
00
Aug 13, 2026

Taiho and Cullinan's zipalertinib succeeds in phase 3 lung cancer trial

Taiho Oncology and Cullinan Therapeutics announced their next-generation EGFR inhibitor zipalertinib significantly improved progression-free survival in a registrational phase 3 trial for first-line treatment of advanced non-small cell lung cancer. The results position the drug as a competitor to multiple approved medicines in the EGFR-mutated lung cancer market.

Aug 13, 2026·4 sources
00
Aug 11, 2026

Skylark Bio doses first patient in gene therapy trial for GJB2-related deafness

Skylark Bio has dosed the first patient in its SONIX Phase 1/2 trial of SKY-GJB2, a gene therapy targeting GJB2-related hearing loss, the most common genetic cause of pediatric deafness. The trial follows earlier breakthrough gene therapy treatments that restored hearing in children born deaf.

Aug 11, 2026·3 sources
00
Aug 10, 2026

Sionna Therapeutics halts cystic fibrosis drug development after trial failure

Sionna Therapeutics discontinued development of its experimental cystic fibrosis pill after it failed to show meaningful benefit when added to standard treatment in a mid-stage trial, causing shares to plunge.

Aug 10, 2026·2 sources
00

Silence Therapeutics reports positive Phase 2 trial results for divesiran in rare blood cancer

Silence Therapeutics announced that its Phase 2 SANRECO trial of divesiran met its primary endpoint in patients with polycythemia vera, a rare blood cancer, with data showing the treatment stabilized red blood cell levels and reduced phlebotomies to 0.2 per patient over 36 weeks. The company's stock rallied significantly on the news.

Aug 10, 2026·9 sources
00
Aug 6, 2026

Tarsus Pharmaceuticals to Acquire Alkeus for Up to $800M, Gaining Late-Stage Stargardt Disease Drug

Tarsus Pharmaceuticals agreed to acquire privately-held Alkeus Pharmaceuticals for $450 million upfront and up to $800 million total, gaining gildeuretinol (ALK-001), a Phase 3 oral therapy for Stargardt disease. The rare genetic eye condition affects over 36,000 people in the U.S. and currently has no FDA-approved treatment, with pivotal trial data expected in late 2029.

Aug 6, 2026·5 sources
00
Aug 5, 2026

UK Scientists Successfully Trial First 'Fridge-Free' Vaccines in Patients

British researchers have conducted the first successful clinical trials of vaccines that do not require refrigeration, a breakthrough that could address the problem of half of all vaccines being discarded due to cold chain failures.

Aug 5, 2026·3 sources
00

UK Approves First Trial of Moderna-Oxford mRNA Vaccine to Prevent Lynch Syndrome Cancers

UK regulators have authorized the INTERCEPT-Lynch Phase 1/2 trial of mRNA-4194, a preventive cancer vaccine developed by Moderna and the University of Oxford targeting people with Lynch syndrome, an inherited condition affecting 1 in 300 people with up to 80% lifetime cancer risk. The trial will begin dosing in summer 2026.

Aug 5, 2026·9 sources
00
Jul 31, 2026

Novo Nordisk's experimental drug fails to reduce heart attacks and strokes in large study

Novo Nordisk's experimental inflammation-targeting drug failed to reduce the risk of heart attacks and strokes in a closely watched large clinical trial, a setback for the drugmaker's growth prospects beyond obesity and diabetes.

Jul 31, 2026·2 sources
00
Jul 29, 2026

Latigo reports positive mid-stage trial results for pain drug competing with Vertex's Journavx

Latigo has announced successful mid-stage clinical trial results for its non-opioid pain medication, positioning it as a potential competitor to Vertex Pharmaceuticals' pain drug Journavx in a field historically marked by development failures.

Jul 29, 2026·1 source
00
Jul 28, 2026

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.

Jul 28, 2026·3 sources
00
Jul 27, 2026

Chinese Drugmaker Innocare Reports Positive Late-Stage Trial Results for Psoriasis Oral Treatment

Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.

Jul 27, 2026·3 sources
00

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00
Jul 26, 2026

Silver diamine fluoride stops tooth decay in children without drilling in major U.S. trial

A major U.S. clinical trial found that silver diamine fluoride, a liquid brushed onto cavities in seconds, stopped decay in more than half of treated cases. The treatment could spare many young children from pain, infection, and surgery.

Jul 26, 2026·1 source
00
Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources
00

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.

Jul 23, 2026·9 sources
00
Jul 18, 2026

Fluvoxamine shows promise for long COVID fatigue in clinical trial

A randomized clinical trial of 399 adults found that the low-cost antidepressant fluvoxamine significantly reduced fatigue and improved quality of life in people struggling with long COVID symptoms.

Jul 18, 2026·1 source
00
Jul 17, 2026

GSK halts development of chronic cough drug after late-stage trial failures

GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.

Jul 17, 2026·2 sources
00
Jul 16, 2026

Serum Institute of India to Manufacture Experimental TB Vaccine M72/AS01E in Partnership with Gates Medical Research Institute

The Serum Institute of India has signed an agreement with the Gates Medical Research Institute to manufacture M72/AS01E, a novel tuberculosis vaccine candidate currently in late-stage clinical trials. If approved, it would be the first new TB vaccine in over 100 years, with Serum Institute planning to invest over $100 million in production.

Jul 16, 2026·3 sources
00

Kalshi launches prediction markets for clinical trials and FDA drug approvals

Prediction market platform Kalshi will begin taking bets on the outcomes of clinical trials and FDA regulatory reviews, making drug-development odds public for the first time and expanding into biotechnology.

Jul 16, 2026·3 sources
00
Jul 14, 2026

Experimental Alzheimer's drug targeting tau protein shows promise in slowing cognitive decline

An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.

Jul 14, 2026·8 sources
00

Semaglutide may slow biological aging in adults with HIV

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.

Jul 14, 2026·1 source
00
Jul 13, 2026

GSK's Cancer Drug Jemperli Meets Primary Goal in Mid-Stage Rectal Cancer Trial

GSK announced its cancer drug Jemperli achieved clinically significant rates of patients showing no detectable signs of cancer for one year or more in a mid-stage rectal cancer trial.

Jul 13, 2026·1 source
00
Jul 4, 2026

Phase Ib Trial Shows Safety of Personalized Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma

Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.

Jul 4, 2026·2 sources
00
Jul 2, 2026

Roche's divarasib outperforms Amgen and Bristol Myers Squibb drugs in Phase 3 lung cancer trial

Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.

Jul 2, 2026·4 sources
00
Jun 30, 2026

BeOne Medicines' Brukinsa Meets Primary Endpoint in Phase 3 Frontline Mantle Cell Lymphoma Trial

BeOne Medicines announced positive Phase 3 results from the MANGROVE trial, showing Brukinsa plus rituximab reduced the risk of disease progression or death by 43% compared to bendamustine plus rituximab in frontline mantle cell lymphoma patients. The combination represents a potential chemotherapy-free treatment option.

Jun 30, 2026·4 sources
00
Jun 29, 2026

AbbVie and Genmab's Epkinly Combination Meets Primary Endpoint in Phase 3 Trial for Relapsed/Refractory DLBCL

The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.

Jun 29, 2026·6 sources
00
Jun 24, 2026

Ollin Biosciences Raises $330 Million for Late-Stage Eye Disease Drug Trials

Texas-based biotech Ollin Biosciences secured $330 million in funding to advance late-stage clinical studies of its experimental eye disease treatment, representing one of the largest recent funding rounds in ophthalmology.

Jun 24, 2026·2 sources
00
Jun 23, 2026

US Provides Experimental Ebola Treatment for Clinical Trials in Congo Outbreak

The United States has supplied doses of an experimental antibody drug from Mapp Biopharmaceutical to support clinical trials addressing the expanding Ebola outbreak in the Democratic Republic of Congo, according to a Health Department spokesperson.

Jun 23, 2026·2 sources
00

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 2026·2 sources
00
Jun 22, 2026

FDA Launches Initiative to Accelerate Drug Development from Early to Late-Stage Trials

The U.S. Food and Drug Administration announced a series of measures designed to speed up drug research across all stages, from early investigational studies through late-stage clinical trials, in an effort to compete with China and develop treatments more quickly.

Jun 22, 2026·2 sources
00
Jun 12, 2026

FDA Approves Belzutifan Plus Pembrolizumab as Adjuvant Therapy for Clear Cell Renal Cell Carcinoma

The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.

Jun 12, 2026·3 sources
00
Jun 9, 2026

First human receives cellular reprogramming therapy in landmark anti-aging clinical trial

The first participant has been treated in a groundbreaking clinical trial testing cellular reprogramming technology designed to rejuvenate aging cells. This marks the first time such reverse-aging therapy has been administered to a human.

Jun 9, 2026·2 sources
00
Jun 8, 2026

Zealand Pharma Shares Plunge 25% After Safety Data Raises Concerns Over Experimental Weight Loss Drug

Shares of Danish drugmaker Zealand Pharma dropped as much as 26% after new safety data on its experimental obesity medicine raised investor concerns over potential side effects.

Jun 8, 2026·1 source
00

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.

Jun 8, 2026·2 sources
00
Jun 4, 2026

ADC Therapeutics Blood Cancer Drug Trial Shows More Deaths Despite Meeting Primary Endpoint

ADC Therapeutics shares plunged 53% in premarket trading after a late-stage study of its blood cancer drug showed more deaths among treated patients, despite meeting its main goal. The safety signal represents a significant setback for the company's development program.

Jun 4, 2026·1 source
00
Jun 2, 2026

NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine

Longevity-focused biotech startup NewLimit announced a $435 million Series C funding round as it prepares to launch its first clinical trial of a liver medicine, marking one of the largest recent raises in the longevity space.

Jun 2, 2026·1 source
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
May 31, 2026

Experimental drug daraxonrasib nearly doubles survival time for pancreatic cancer patients in clinical trial

Clinical trial results show that daraxonrasib, an experimental daily pill, nearly doubled overall survival rates for patients with advanced pancreatic cancer compared to traditional chemotherapy. Medical experts are calling the results a 'game changer' for treating one of the deadliest forms of cancer.

May 31, 2026·8 sources
00

Johnson & Johnson's Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study

J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.

May 31, 2026·2 sources
00

Akeso and Summit's Lung Cancer Drug Extends Survival by 34% in Late-Stage China Trial

Ivonescimab, an experimental drug combining two immunotherapy mechanisms, reduced the risk of death by 34% compared to standard immunotherapy in patients with advanced squamous non-small cell lung cancer in a closely watched Chinese trial. The drug helped patients live 15% longer than BeOne Medicines' Tevimbra.

May 31, 2026·3 sources
00

Novartis Experimental Radiopharma Drug Shows Anti-Tumor Activity in Early Prostate Cancer Study

Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.

May 31, 2026·1 source
00
May 30, 2026

Multi-fraction stereotactic radiation improves local control for large brain metastases in phase 3 trial

The first randomized phase 3 trial comparing radiation schedules found that delivering stereotactic radiation over three to five sessions after surgery significantly improved local control and reduced cancer recurrence at the surgical site for patients with large, resected brain metastases compared with single-fraction treatment.

May 30, 2026·3 sources
00
May 29, 2026

Bristol Myers Squibb's Mezigdomide Delays Disease Progression in Late-Stage Multiple Myeloma Trial

Bristol Myers Squibb announced its experimental oral drug mezigdomide successfully delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to prior treatments.

May 29, 2026·1 source
00

Agios Pharmaceuticals Discontinues Blood Cancer Drug Program After Mid-Stage Trial Failure

Agios Pharmaceuticals announced it will stop developing its experimental drug for a form of blood cancer after a mid-stage trial failed to show sufficient benefit, marking a setback for the rare disease program.

May 29, 2026·1 source
00
May 25, 2026

Eli Lilly's Gene-Editing Therapy Reduces Cholesterol by 62% in Early Clinical Trial

Eli Lilly reported that a high dose of its gene-editing therapy from Verve Therapeutics reduced cholesterol levels by 62% in participants in an early-stage clinical trial, representing a significant advance in gene-editing treatments for cardiovascular disease.

May 25, 2026·1 source
00
May 23, 2026

Indian Council of Medical Research Implements Single-Window Ethics Approval System

ICMR has replaced the fragmented site-by-site ethics approval process with a unified system for multicentre medical studies, streamlining research authorization across India.

May 23, 2026·1 source
00
May 21, 2026

Eli Lilly's Retatrutide Achieves Up to 30% Weight Loss in Phase 3 TRIUMPH-1 Trial

Eli Lilly announced positive results from its Phase 3 TRIUMPH-1 trial showing retatrutide, an experimental triple-agonist obesity drug, achieved average weight loss of 28.3% at 80 weeks and 30.3% at 104 weeks on the highest dose, matching weight reduction levels typically seen with bariatric surgery.

May 21, 2026·3 sources
00
May 16, 2026

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.

May 16, 2026·1 source
00
May 14, 2026

Biogen Advances Tau-Targeting Alzheimer's Drug to Phase 3 Despite Mixed Phase 2 Results

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies following a Phase 2 trial that showed mixed results.

May 14, 2026·1 source
00

Regenxbio's Duchenne Gene Therapy Succeeds in Clinical Trial, Paving Way for FDA Submission

Regenxbio announced its experimental gene therapy for Duchenne muscular dystrophy succeeded in a clinical trial, enabling the company to move forward with an FDA submission.

May 14, 2026·1 source
00

CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines secured $122 million in funding to advance its CAR-T therapy candidates through human trials, alongside a company rebrand and expanded pipeline.

May 14, 2026·1 source
00
May 12, 2026

Astellas Returns to Gene Therapy for Rare Disease XLMTM After Previous Trial Disaster

Five years after a disastrous trial where some boys died while others had astonishing recoveries, Astellas is returning with a revised gene therapy treatment for X-linked myotubular myopathy (XLMTM), offering new hope to a devastated rare disease community.

May 12, 2026·2 sources
00
May 5, 2026

Johnson & Johnson's IBD Therapy Fails to Meet Primary Endpoint in Clinical Trial

Johnson & Johnson's closely watched inflammatory bowel disease therapy failed to show statistically significant improvement in patients during clinical trials, representing a setback for the pharmaceutical giant's gastroenterology pipeline.

May 5, 2026·1 source
00
May 4, 2026

Latus Bio Raises $42 Million to Advance Huntington's Disease Gene Therapy Trial

Latus Bio secured $42 million in funding as it prepares to seek FDA approval to begin a clinical trial for its gene therapy targeting Huntington's disease, a progressive neurodegenerative disorder.

May 4, 2026·1 source
00
May 3, 2026

Experimental KRAS G12D Cancer Drug Shows Tumor Shrinkage in First-in-Human Trial

Setidegrasib, an investigational targeted therapy drug, demonstrated ability to slow cancer growth and shrink tumors in a first-in-human clinical trial published in the New England Journal of Medicine, targeting a previously difficult-to-treat cancer mutation.

May 3, 2026·1 source
00
May 2, 2026

GLP-1 Drug Semaglutide Reduces Heavy Drinking Days by 50% in Alcohol Use Disorder Trial

A clinical trial of 108 adults with obesity and alcohol use disorder found that once-weekly semaglutide injections reduced heavy drinking days in the past 30 days by an average of roughly 12 days, representing a 50% reduction compared to placebo.

May 2, 2026·1 source
00
Apr 29, 2026

Boehringer Ingelheim's Obesity Drug Shows 16.6% Weight Loss in Clinical Trial

Boehringer Ingelheim reported that its experimental obesity drug achieved 16.6% weight loss in clinical trials, marking another entrant in the competitive GLP-1 weight loss drug market.

Apr 29, 2026·1 source
00

FDA Launches Real-Time Clinical Trial Monitoring Initiative Using AI

The FDA announced a new program to monitor clinical trials in real-time using cloud-based systems and AI, allowing regulators to see trial endpoints as they occur rather than waiting for final results.

Apr 29, 2026·2 sources
00
Apr 28, 2026

Minimally Invasive Heart Procedure Outperforms Medication for Advanced Atrial Fibrillation in Major International Trial

A major international clinical trial found that a minimally invasive heart procedure may be a better first-line treatment than medication for people with advanced forms of atrial fibrillation, offering improved outcomes for patients with this common heart rhythm disorder.

Apr 28, 2026·1 source
00

High-Precision Radiation Therapy Reduces Life-Threatening Heart Arrhythmias by 80%

Two studies report that targeted, noninvasive radiation therapy (proton beam therapy) reduced episodes of life-threatening cardiac arrhythmias by nearly 80% in critically ill patients, representing the first large-scale and first-in-human evidence for this approach.

Apr 28, 2026·2 sources
00
Apr 27, 2026

Veradermics' Hair Loss Drug Succeeds in Late-Stage Clinical Trial

Veradermics reported positive results from a late-stage trial of its hair loss treatment, positioning the company as one of the most advanced players in the hair loss field amid surging investor interest.

Apr 27, 2026·1 source
00

Intellia Reports Positive Pivotal Trial Results for CRISPR-Based Treatment of Rare Swelling Disease

Intellia Therapeutics announced that its CRISPR-based gene editing treatment reduced swelling attacks in a pivotal trial for hereditary angioedema, a rare genetic disease. The results advance the CRISPR field's one-and-done treatment approach toward potential regulatory approval.

Apr 27, 2026·1 source
00
Apr 25, 2026

Continuous Glucose Monitors Significantly Improve Blood Sugar Control in Type 2 Diabetes Patients on Insulin

A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.

Apr 25, 2026·1 source
00
Apr 24, 2026

Paxlovid Does Not Reduce Hospitalization in Vaccinated COVID Patients Despite Faster Recovery

Two major clinical trials led by St. Michael's Hospital and Oxford University found that Paxlovid does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, though it helps them recover faster.

Apr 24, 2026·2 sources
00
Apr 23, 2026

Low-Dose Triple-Pill Combination Reduces Recurrent Stroke Risk by 40% in Global Trial

A global clinical trial found that GMRx2, a single pill combining three low-dose blood pressure medications, significantly reduced the risk of recurrent stroke in patients with intracerebral hemorrhage and high blood pressure by approximately 40%.

Apr 23, 2026·1 source
00
Apr 22, 2026

Gene Therapy for Inherited Deafness Shows Lasting Hearing Restoration Years After Treatment

International clinical trial results show that gene therapy for a rare form of genetic deafness successfully restored hearing in 90% of participants, with improvements lasting years after treatment. The study was co-led by Mass General Brigham and China's Eye & ENT Hospital of Fudan University.

Apr 22, 2026·2 sources
00

Roche Presents Multiple Sclerosis Drug Data Ahead of Regulatory Submission

Swiss drugmaker Roche presented latest clinical trial data for its experimental multiple sclerosis drug at a major conference, setting the stage for regulatory approval submissions, though safety questions remain under scrutiny.

Apr 22, 2026·1 source
00

Kyverna Therapeutics Plans FDA Submission for Stiff Person Syndrome Cell Therapy

Kyverna Therapeutics announced plans to submit its one-time CAR-T cell therapy for stiff person syndrome to the FDA after late-stage trial showed improvements in mobility and reduced disabilities in patients with the rare neurological disease.

Apr 22, 2026·1 source
00

Immunotherapy Shows Clinical Benefit in Advanced Colorectal Cancer as First-Line Treatment

Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.

Apr 22, 2026·2 sources
00
Apr 21, 2026

BioAge Labs Reports Experimental Cardiovascular Drug Significantly Reduced Inflammation in Early Study

BioAge Labs announced its investigational pill for cardiovascular risk prevention significantly reduced inflammation markers in an early-stage clinical study, representing potential progress in heart disease prevention.

Apr 21, 2026·1 source
00

CAR-T Therapy Shows Promise in Preventing Multiple Myeloma in High-Risk Patients

Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.

Apr 21, 2026·2 sources
00
Apr 20, 2026

Improved Oral Hygiene Reduces Hospital-Acquired Pneumonia Risk by 60% in Major Trial

A landmark trial presented at ESCMID Global 2026 demonstrates that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia by 60%, offering a simple intervention to prevent a serious complication.

Apr 20, 2026·1 source
00

India Approves New Tuberculosis Vaccines for Adolescents Following Large Phase III Trial

India has approved new tuberculosis vaccines for adolescents, backed by a large, independent Phase III clinical trial led and funded by public science institutions. The vaccines represent a significant breakthrough in TB prevention, though officials note they are not a complete solution.

Apr 20, 2026·1 source
00
Apr 17, 2026

Roche Launches New Phase 3 Trial of Elevidys for European Approval

Roche is initiating another Phase 3 clinical trial of the controversial Duchenne muscular dystrophy gene therapy Elevidys, aiming for potential approval in European markets.

Apr 17, 2026·1 source
00

First-in-Human Trial Shows Liver Transplant Patients Can Stop Immunosuppressants After Cell Therapy

UPMC and University of Pittsburgh researchers successfully weaned multiple liver transplant patients off all immunosuppressant drugs for over three years using a pre-transplant cell therapy approach, representing a potential breakthrough in organ transplantation.

Apr 17, 2026·2 sources
00

Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial

Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.

Apr 17, 2026·1 source
00
Apr 16, 2026

New Anti-Clotting Drug Asundexian Reduces Stroke Risk Without Increased Bleeding

Large international trial found that investigational drug asundexian reduces stroke risk in people who recently experienced stroke or TIA without added bleeding complications.

Apr 16, 2026·1 source
00

Top claims

  • ▪The FDA approved Roche Holding AG's oral breast cancer pill Wilserdly for patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer
  • ▪The approval of Wilserdly expands Roche Holding AG's footprint in an emerging class of medicines aimed at reshaping treatment for HR-positive breast cancer
  • ▪ESR1 gene mutations indicate that an estrogen receptor-positive breast tumor is developing resistance to standard therapies

People involved

Robert F. Kennedy Jr.Sam AltmanJia Guo

Subtopics

Drug Policy, Pricing & Approval140Drug Approval and Clinical Trials115Cancer & Oncology56Pharma50Drug development41Clinical Trial Design & Evaluation37Pharmaceutical Industry33Cancer treatment30Cancer treatment breakthroughs30Clinical evaluation30Oncology22FDA drug approval18Weight management17Cancer immunotherapy16Cancer Types16Gene therapy16Immunotherapy15Vaccines and Immunization Policy15Clinical trial endpoints14Drug safety14Lifestyle, Wellness and Nutrition14Rare diseases14Cancer Treatment & Therapies13Public healthcare12

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories